B
Bullisch
Bullisch · 25%ANL
$2.06
Szenariopreis
$11.030
-0.967 (-8.77%)Zum Schluss
Loading chart…
- Hoch
- 12.040
- Eröffnung
- 11.890
- Volumengewichteter Durchschnittskurs
- 11.33
- Volumen
- 336.59K
- Marktkap.
- 136.89M
- Tief
- 10.930
- Umsatz
- 3.81M
- EV/EBITDA, TTM
- -293.83
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.
KI-Analyse of Adlai Nortye Group Ltd (ANL)
HaltenAdlai Nortye Ltd (ANL) is currently not a good buy due to its very low RSI of 28.408, indicating that it is oversold, and a significant 5-day price drop of 29.39%. While it has shown impressive year-to-date growth of 699.28%, the recent sharp decline raises concerns. The main risk is the negative earnings per share forecast, with a projected EPS of -0.54 for Q4 2024, which could impact investor sentiment.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Adlai Nortye Group Ltd (ANL) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -4.27.
Alphio-AI-Kursszenarien für ANL
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ANL halten
Event-Zeitleiste
News
9.009-08NASDAQ.COMAdlai Nortye Initiates Global Phase I Trial for AN4035
8.509-08NewsfilterFirst-in-Class CEACAM5-Targeting ADC Clinical Trial Initiated
- 9.508-14Newsfilter
Adlai Nortye Reports H1 2026 Financial Results and Clinical Updates
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
9.507-07NASDAQ.COMInnovative Eyewear Reports Significant Q2 Sales Growth
ANL FAQ – beantwortet von Alphio AI
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment. It operates in the Healthcare sector.
Adlai Nortye Ltd (ANL) is currently not a good buy due to its very low RSI of 28.408, indicating that it is oversold, and a significant 5-day price drop of 29.39%. While it has shown impressive year-to-date growth of 699.28%, the recent sharp decline raises concerns. The main risk is the negative earnings per share forecast, with a projected EPS of -0.54 for Q4 2024, which could impact investor sentiment.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.